

Research

## Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema

Fiorella Calabrese\*<sup>1</sup>, Cinzia Giacometti<sup>†1</sup>, Bianca Beghe<sup>†2</sup>, Federico Rea<sup>†3</sup>,  
Monica Loy<sup>†3</sup>, Renzo Zuin<sup>†2</sup>, Giuseppe Marulli<sup>†3</sup>, Simonetta Baraldo<sup>†2</sup>,  
Marina Saetta<sup>†2</sup> and Marialuisa Valente<sup>†1</sup>

Address: <sup>1</sup>Institute of Pathology, University of Padua, Italy, <sup>2</sup>Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Padua, Italy and <sup>3</sup>Department of Gastroenterological Sciences, Section of Thoracic Surgery, University of Padua, Italy

Email: Fiorella Calabrese\* - [fiorella.calabrese@unipd.it](mailto:fiorella.calabrese@unipd.it); Cinzia Giacometti - [cinziagiacometti@virgilio.it](mailto:cinziagiacometti@virgilio.it);  
Bianca Beghe - [bianca.beghe@unipd.it](mailto:bianca.beghe@unipd.it); Federico Rea - [federico.rea@unipd.it](mailto:federico.rea@unipd.it); Monica Loy - [chirtor@unipd.it](mailto:chirtor@unipd.it);  
Renzo Zuin - [renzo.zuin@unipd.it](mailto:renzo.zuin@unipd.it); Giuseppe Marulli - [giuseppe.marulli@unipd.it](mailto:giuseppe.marulli@unipd.it); Simonetta Baraldo - [simonetta.baraldo@unipd.it](mailto:simonetta.baraldo@unipd.it);  
Marina Saetta - [marina.saetta@unipd.it](mailto:marina.saetta@unipd.it); Marialuisa Valente - [marialuisa.valente@unipd.it](mailto:marialuisa.valente@unipd.it)

\* Corresponding author †Equal contributors

Published: 10 February 2005

Received: 29 July 2004

*Respiratory Research* 2005, **6**:14 doi:10.1186/1465-9921-6-14

Accepted: 10 February 2005

This article is available from: <http://respiratory-research.com/content/6/1/14>

© 2005 Calabrese et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Apoptosis has recently been proposed to contribute to the pathogenesis of emphysema.

**Methods:** In order to establish if cell fate plays a role even in end-stage disease we studied 16 lungs (9 smoking-associated and 7  $\alpha$ 1 antitrypsin (AAT)-deficiency emphysema) from patients who had undergone lung transplantations. Six unused donor lungs served as controls. Apoptosis was evaluated by TUNEL analysis, single-stranded DNA laddering, electron microscopy and cell proliferation by an immunohistochemical method (MIB1). The role of the transforming growth factor (TGF)- $\beta$ 1 pathway was also investigated and correlated with epithelial cell turnover and with the severity of inflammatory cell infiltrate.

**Results:** The apoptotic index (AI) was significantly higher in emphysematous lungs compared to the control group ( $p \leq 0.01$ ), particularly if only lungs with AAT-deficiency emphysema were considered ( $p \leq 0.01$  vs  $p = 0.09$ ). The proliferation index was similar in patients and controls ( $1.9 \pm 2.2$  vs  $1.7 \pm 1.1$ ). An increased number of T lymphocytes was observed in AAT-deficiency lungs than smoking-related cases ( $p \leq 0.05$ ). TGF- $\beta$ 1 expression in the alveolar wall was higher in patients with smoking-associated emphysema than in cases with AAT-deficiency emphysema ( $p \leq 0.05$ ). A positive correlation between TGF- $\beta$ RII and AI was observed only in the control group ( $p \leq 0.005$ ,  $r^2 = 0.8$ ). A negative correlation was found between the TGF- $\beta$  pathway (particularly TGF- $\beta$ RII) and T lymphocytes infiltrate in smoking-related cases ( $p \leq 0.05$ ,  $r^2 = 0.99$ ).

**Conclusion:** Our findings suggest that apoptosis of alveolar epithelial cells plays an important role even in end-stage emphysema particularly in AAT-deficiency disease. The TGF $\beta$ -1 pathway does not seem to directly influence epithelial turnover in end-stage disease. Inflammatory cytokine different from TGF- $\beta$ 1 may differently orchestrate cell fate in AAT and smoking-related emphysema types.

## Background

Pulmonary emphysema, a significant global health problem, is a pathological condition characterized by enlargement of the airspaces distal to the terminal bronchiole, destruction of the alveolar walls, without and/or with mild fibrosis [1]. To date the pathogenesis remains enigmatic. The most prevailing hypothesis since the 1960s has been the elastase/antielastase imbalance theory of inflammation [2]. Briefly, the concept is that activated inflammatory cells release large quantities of elastases, overwhelming local antiprotease activity with consequent damage to the alveolar wall matrix [3]. However the emphasis on alveolar matrix destruction by a combination of inflammation and excessive proteolysis has failed to fully explain the loss of lung tissue, particularly when compared to alterations seen in other inflammatory lung diseases.

Recently more attention has been paid to alveolar epithelial injury in addition to alveolar matrix destruction. The presence of apoptosis has recently been described in animal models of emphysema [4,5] and in a few studies of human disease [6-9].

The majority of investigations have focused the attention on smoking-related emphysema keeping in mind that cigarette smoking was the main cause of apoptotic cell death. Cigarette smoke may induce alveolar cell apoptosis either directly by a cytotoxic effect on pneumocytes or indirectly by decreasing the production of vascular endothelial growth factor (VEGF) via altered epithelial cells [7]. To date smoking-associated centrilobular emphysema is the only studied form of emphysema in which apoptosis, and more recently also proliferation, have been investigated [9]. Alterations of lung epithelial cell turnover in end-stage emphysema, either smoking-associated emphysema or  $\alpha$ 1-antitrypsin (AAT)-deficiency emphysema, are up to now not well distinguished.

Moreover apoptotic phenomenon has been previously investigated in moderate/severe smoking-related forms of emphysematous lungs obtained almost exclusively from lung volume reduction surgery [6,7,9]. If cell fate is a stable, progressive and/or a decreasing process in end-stage disease is to date unknown.

Among the growth factors, transforming growth factor (TGF)- $\beta$ 1 could play a crucial role in the remodeling process occurring in emphysematous parenchyma. TGF- $\beta$ 1, other than its known profibrogenetic [10] and anti-inflammatory effects [11,12], has an important influence on epithelial cell growth [14]. It has been demonstrated that it has an inhibitory effect on the growth of lung epithelial cells, particularly for airway epithelium [14,15].

The cytokine has been shown to be over-expressed in patients with a history of smoking and chronic obstructive pulmonary disease (COPD) [16,17]. Paracrine (mainly produced by macrophages) and autocrine (released by epithelial cells) activity of this growth factor could play an important role in the loss of the alveolar walls by inducing apoptotic cell death.

In the present work the degree of apoptotic cell death and epithelial proliferation in the lungs of patients with different types of end-stage emphysema was studied. The severity of inflammatory cell infiltrate (ICI) was also quantified and correlated with epithelial cell turnover. Further, the TGF- $\beta$ 1 pathway was detected and correlated with the apoptotic index (AI), the proliferative index (PI) and the ICI.

## Methods

### Lung tissue preparation

Lung tissue used in the present study comprised material from 16 patients undergoing lung transplantation for end-stage emphysema at the Thoracic Surgery Unit of the University of Padua Medical School. Cold ischemia preservation was 60 minutes and 120 minutes, respectively, for single and double lung transplantations. Small-sized pieces from all lobes were cut and immediately fixed in Karnovsky's solution for electron microscopy. The lungs were then gently fixed in 10% phosphate-buffered formalin by airway perfusion and processed for sectioning (3  $\mu$ m). Samples were selected from specimens that showed features of excellent tissue preservation and adequate lung inflation. In particular, large thin blocks approximately 30  $\times$  25 mm were cut from the subpleural areas of the apical anterior and lingular segments of the upper lobes, as well as the apical and basal segments of the lower lobes. A more centrally placed block was taken to sample the segmented airways and blood vessels. The right lung was sampled in the same way with the middle lobe being treated in the same way as the lingula [18]. Adult control lungs were obtained from unused donor lungs for transplantation (6 cases). The Local Research Ethics Committee approved the study.

### TUNEL analysis

The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling method (TUNEL) was used to investigate the presence of apoptosis. Sections were processed in accordance with Gavrieli et al's method [19]. Briefly, after deparaffinization and rehydration, sections were digested with proteinase K (Boehringer Mannheim, Mannheim, Germany) at a concentration of 20  $\mu$ g/ml for 15 minutes. The slides were then incubated with TdT/biotinylated dUTP diluted in buffer (Boehringer Mannheim, Mannheim, Germany). The slides were developed by using diaminobenzidine and 30 ml hydrogen

peroxide. For negative controls, some slides were incubated in buffer without TdT or biotinylated UTP. For positive controls, some slides were incubated with 1 µg/ml DNase (Sigma-Aldrich, Milan, Italy).

#### **Electron microscopy**

Lung specimens fixed in Karnovsky's solution (2% paraformaldehyde, 2.5% glutaraldehyde in Millonig, pH 7.3) for 24 hours were post-fixed with 1% osmium tetroxide (Millonig, pH 6.8) for 1 hour, and then progressively dehydrated in alcohol and embedded in epon. Semi-thin sections were stained with 0.1% toluidine blue for light microscopic examination. Ultra-thin sections were stained with uranyl acetate and lead citrate for transmission electron microscopy performed using a Hitachi H-7000 (Hitachi Ltd., Tokyo, Japan).

#### **Oligonucleosomal-length DNA laddering**

The presence of oligonucleosomal-length DNA cleavage was investigated with APO-DNA1 (Maxim Biotech Inc, San Francisco, CA, USA) in 12 cases (4 AAT-emphysema patients, 4 smoking-related emphysema patients and 4 controls) in which frozen tissue was available. Briefly, DNA was obtained from lung tissue samples using proteinase K-phenol extraction. Dephosphorylated adaptors were ligated to 5' phosphorylated blunt ends with T<sub>4</sub> DNA ligase to 500 ng of lung sample DNA (for 16 h at 16°C). These then served as primers in LM-PCR under the following conditions: hot start (72°C for 8 min), 30 cycles (94°C for 1 min, and 72°C for 3 min) and extension (72°C for 15 min). Every reaction set included thymus DNA as a positive control and normalization of the amount of reaction products. Amplified DNA was subjected to electrophoresis on 1.2% agarose gel containing ethidium bromide. Images were scanned and the DNA fragmentation levels were based on the density of the bands ranging between 1000 base pairs (bp) and 300 bp. The percentage of DNA fragmentation was quantified by scanning densitometry.

#### **Immunohistochemistry for TGF-β1, TGF-βRII and MIB1**

All lung sections were subjected to antigen retrieval by heating in a microwave oven on high power for 8 minutes in 0.01 mol/l citrate buffer (pH 6.0) and then incubated with a mouse monoclonal anti-TGF-β<sub>1</sub>-β<sub>2</sub> and-β<sub>3</sub> primary antibody to active TGF-β1 (150 µg/ml; dilution 1:20, Genzyme Diagnostics, Cambridge, MA), with polyclonal antibody against TGF-β receptor type II (200 µg/ml, dilution 1:200, Santa Cruz Biotechnology Inc., Santa Cruz) and monoclonal MIB-1 antibody (1:50 Dako, Santa Barbara, CA, U.S.A.), which recognizes the Ki-67 antigen in paraffin-embedded tissue sections. Immunohistochemical investigations were done on the sections from the same paraffinembedded specimens processed for TUNEL analysis.

The detection system was the Vectastain ABC kit (Vector Peterborough, UK) with 3-amino-9-ethylcarbazole (for TGF-β1, TGF-βRII) and with a mixture of 3,3'-diaminobenzidine tetrahydrochloride (Dako) and hydrogen peroxide as the chromogenic substrates. Sections were counterstained with Mayer's hematoxylin.

#### **Immunohistochemistry for inflammatory cell infiltrate (ICI)**

In all samples, immunohistochemistry for the characterization of ICI was carried out by using the following antibody panel: CD20 (1:100), CD45RO (1:100), CD4 (1:20), CD8 (1:50), CD3 (1:100), CD68 (1:50) (Dako, Santa Barbara, CA, U.S.A.). The detection system was the Vectastain ABC kit, as described above.

For all immunohistochemistry experiments, negative controls were performed by incubation of the sections with the omission of primary antibody and using the antibody diluents alone or the appropriate non-immune IgG in each case.

#### **Double immune-labeling**

For simultaneous detection of DNA fragmentation and cell proliferation a double labeling was also performed. The TUNEL technique was first performed and the staining achieved was diaminobenzidine as chromogen. For MIB1 immunolocalization in the second staining sequence the sections were stained with 5-bromo-4-chloro-3-indoxyl phosphate/nitro blue tetrazolium (BCIP/NBT alkaline phosphatase Kit II, Vector Laboratories (Vector Peterborough, UK).

#### **Image analysis**

Immunoassay for TGF-β1 and TGF-βRII was detected by using digital quantitative analysis (Image Pro Plus software version 4.1, Media Cybernetics, Silver Spring MD) as previously described [13]. Quantification of TUNEL, MIB1 positive cells and ICI was restricted to the alveolar wall. Images for each lung section from the upper and lower lobes were acquired with a 40X lens.

In each case at least 50 microscopic randomly chosen fields were analyzed. A total of 5,000 epithelial cells were counted for AI and PI and the values were expressed as percentages.

#### **Statistical analysis**

To avoid observer bias the cases were coded and measurements were made without knowledge of clinical data. Differences between groups were detected using the analysis of variance for clinical data and the Kruskal-Wallis test for histological data. The Mann-Whitney U test was performed after the Kruskal-Wallis test when appropriate. The statistical tests used were two-sided.

**Table 1: Subject Characteristics**

Case	Sex	Age	Emphysema type	Packs/year	FEV <sub>1</sub> *	FEV <sub>1</sub> /FVC*	Transplantation
1	M§	49	AAT deficiency	27	27	27	BSLT*
2	M	59	Smoking	36,5	31	38	RtSLT †
3	F	62	Smoking	7	17	55	BSLT
4	F	62	Smoking	36,5	13	30	LtSLT ‡
5	M	62	Smoking	108	15	45	BSLT
6	F	49	Smoking	73	12	33	BSLT
7	M	47	Smoking	54	22	60	BSLT
8	M	59	AAT deficiency	36,5	20	56	BSLT
9	M	64	Smoking	54	6	42	LtSLT
10	M	63	Smoking	54	24	37	BSLT
11	M	51	AAT deficiency	54	11	25	BSLT
12	M	53	AAT deficiency	108	8	14	BSLT
13	M	45	AAT deficiency	73	17	24	BSLT
14	M	56	Smoking	36,5	15	32	RtSLT
15	F	41	AAT deficiency	54	35	38	BSLT
16	M	51	AAT deficiency	36,5	34	36	BSLT

\*BSLT: bilateral single lung transplantation, † RtSLT: right transplant single lung transplantation, ‡ LtSLT: left transplant single lung transplantation, §M: male, || F: female. FEV<sub>1</sub> and FVC are given as percentages of predicted values.

Correlation coefficients were calculated using Spearman's rank method. Probability values of 0.05 or less were accepted as significant. Group data were expressed as means and SD or as medians and range when appropriate.

## Results

### **Clinical data and histological findings**

Major clinical data for patients with emphysema are shown in Table 1.

Average patient age was  $54.4 \pm 7.5$  years. FEV<sub>1</sub> mean was  $19 \pm 8.9$  (predicted for sex, age, and body weight). Bilateral single lung transplantation was performed in 12 out of 16 patients. All patients had been heavy smokers: 7 were only smoking-associated emphysema cases ( $51 \pm 28$  packs-year) and 9 were both AAT-deficiency emphysema and smoking cases ( $55 \pm 27$  packs-year). For the sake of brevity, the abbreviation AAT-deficiency emphysema for smoking patients with AAT-deficiency will be used throughout the manuscript.

All patients had quit smoking at least 1 year before undergoing surgery.

The average control patient age was  $34 \pm 16.8$  years and cerebral trauma was the cause of death. All the donors stayed less than two days in intensive care without evidence of lung infection or other complications. During artificial ventilation, airway pressure ( $P_{aw}$ ) was  $20,9 \pm 1.5$  mmHg and inspiratory oxygen fraction ( $FI, O_2$ ) was  $0.4 \pm 0.1$ .

All the samples showed various degrees of emphysematous changes. In particular, all the patients with AAT-deficiency showed diffuse destruction of alveolar tissue, consistent with panlobular emphysema. In contrast, relatively preserved lower portions of the lungs were observed in patients with smoking-associated emphysema, consistent with centrilobular emphysema.

### **Immunophenotype analysis**

Emphysema patients had an increased number of ICI (CD20, CD3, CD8, CD68, CD45RO, CD4 and PMN) as compared with controls ( $p \leq 0.01$ ). An increased number of CD3 ( $p \leq 0.05$ ), CD8 ( $p \leq 0.05$ ) and CD45RO ( $p \leq 0.001$ ) was seen in AAT-deficiency emphysema compared to smoking-related emphysema (Table 2).

### **Analysis of epithelial apoptosis and proliferation**

Labeling of the DNA breaks by TUNEL demonstrated positive cells that were localized to peribronchiolar, intra-alveolar and septal sites in both normal and emphysematous lungs. Quantification was limited to the alveolar wall. Apoptotic bodies that were very close to each other were counted as one dying cell. Intra-alveolar apoptotic cells were not included in the cell count.

In emphysematous lungs AI ranged from 0.68 to 11.92 (mean  $6.3 \pm 3.5$ ). The TUNEL-positive cells were more frequently detected within more enlarged alveolar walls. Apoptotic cells and/or bodies were frequently seen in intra-alveolar lumen that presumably represented apoptotic cells detached from the alveolar wall (Fig. 1). AI was significantly higher in patients than in controls ( $6.5 \pm 3.5$


**Table 2: Inflammatory Cells (Total Cells/MM Alveolar Wall)**

	AAT	Smokers	Controls *	P†
CD20	4.77	2.1	0.0	ns
CD3	25.39	17.84	2.5	<0,05
CD8	12.32	5.07	0.99	<0,05
CD68	4.35	6.88	0.75	ns
CD45RO	25.42	8.34	2.31	0,001
CD4	12.1	12.67	1.89	ns
PMN	18.07	20.78	0.0	ns


Definition of abbreviation. PMN: Polymorphonuclear cells

\* The values of control group were all statistically significant compared to both emphysema groups.

† Significant differences between AAT-deficiency and smoking patients.



**Figure 1**  
**AAT-deficiency emphysema case I:** Micrograph showing strong specific staining for DNA strand breaks in the alveolar epithelial cells and in two cells detaching from the wall. TUNEL (original magnification 160x).




**Figure 2**  
**AI in controls vs emphysema patients:** Significantly higher AI was found in emphysema patients ( $6.5 \pm 3.5$  vs  $2.7 \pm 2.6$ ,  $p \leq 0.01$ )  $\diamond$  = AAT-deficiency emphysema;  $\circ$  = smoking-related emphysema.

vs  $2.7 \pm 2.6$ ,  $p \leq 0.01$ ) (Fig 2). If separately compared with the control group only the AAT-deficiency emphysema showed a statistically significant difference ( $p \leq 0.01$  vs  $p = 0.09$ ). Increased levels of oligonucleosomal-length DNA fragments were also detected in emphysema patients, particularly in AAT-deficiency emphysema, than control lungs (Fig. 3a,b). The PI of patients ranged from 0.19% to 4.81% (mean  $1.9 \pm 2.2$ ). Similar numbers of MIB1-positive alveolar septal cells were observed in both types of emphysema and control lungs ( $1.7 \pm 1.1$ ).


TUNEL-positive/MIB1-negative nuclei detected by double staining were seen in all cases, whereas MIB1 was never expressed in any of the TUNEL-positive nuclei (Fig. 4a,b).

In each group, no statistically significant correlations were found between AI and PI as well as between AI/PI and ICI.



**Figure 3**

**Gel-electrophoresis: a)** Oligonucleosomal-length DNA laddering in emphysematous and control lungs. Lane 1: DNA marker; Lanes 2–5: control donor lungs (4 cases); Lanes 6–9: AAT-deficiency emphysema patients (4 cases); Lanes 10–13: smoking-related emphysema patients (4 cases); Lane 14: positive control. **b)** Quantification of DNA laddering based on scanning densitometry of bands approximately between 1000 bp and 300 bp (arrowhead) followed by normalization with the density obtained with the equivalent band of the thymus DNA positive control (lung sample/control = densitometric ratio) which was included in every oligonucleosomal DNA laddering assay.



**Figure 4**  
**Smoking-related emphysema case 3: a)** double labeling TUNEL/MIB1 (marker of cell proliferation) showing two apoptotic cells (dark) and one MIB1-positive cell (blue), on the surface of the same alveolar wall (original magnification 160 $\times$ ). **b)** Note alveolar cell in proliferation close (blue) to apoptotic pneumocyte (dark) (Original magnification 160 $\times$ ).

At electron microscopy typical features of early apoptosis with margination of chromatin at the nuclear membrane and late apoptosis with completely dense nuclear chromatin, including apoptotic bodies in various stages of degradation, were seen in pneumocytes, endothelial cells and fibroblasts. Typical features of reduplication of vessel basal membranes were frequently seen in cases with more evident apoptosis (5 a-f). Ultrastructural analysis showed more frequent mitotic features in type II pneumocytes.

#### **TGF- $\beta$ 1 and TGF- $\beta$ RII receptor analysis**

In emphysema patients and controls TGF- $\beta$ 1 and TGF- $\beta$ RII were localized in bronchiolar and alveolar epithelial cells and macrophages. Quantitative analysis of TGF- $\beta$ 1 measured in the alveolar wall showed no statistically significant difference between emphysema patients and controls. A higher cytokine expression was noted in patients with smoking-associated emphysema compared with AAT-deficiency disease (mean  $8.8 \pm 1.7$  vs  $5.2 \pm 3.9$ ,  $p \leq 0.05$ ) (Fig. 6). A positive significant correlation between TGF- $\beta$ RII and AI ( $p = 0.005$ ;  $r^2 = 0.8$ ) was seen in control lungs (Fig. 7). A significant negative correlation was found between TGF- $\beta$  pathway (particularly TGF- $\beta$ RII) and T lymphocytes infiltrate (CD3+) ( $p \leq 0.05$ ,  $r^2 = 0.99$ ) in smoking-related cases. No correlation was noted between the TGF- $\beta$ 1 pathway (TGF- $\beta$ 1 and its RII) and the AI/ PI of emphysematous lungs.


#### **Discussion**

In the present study we have analyzed for the first time apoptosis and proliferation in different types of end-stage emphysema. The detection of a high AI in emphysematous lungs even in end-stage disease emphasizes the importance of the phenomenon in the development, and overall, in the progression of emphysema.

In general there are two main forms of cell death: oncosis and apoptosis. The latter process results in characteristic biochemical features and cellular morphology such as cell shrinkage condensation and fragmentation of the nucleus into well contained fragments called apoptotic bodies.


Perturbation of normal rates of apoptosis has been implicated in many pathologic conditions such as neuro-vegetative, cardiovascular and liver disorders and cancer [20-22]. As stated in Tuder's recent review on apoptosis and its role in emphysema, cell damage, apoptosis, apoptotic cell removal, and cellular replacement are ongoing and presumably highly regulated in order to maintain homeostasis of the entire alveolar unit. The concept of the irreversible destruction of alveolar walls due to the loss of homeostasis of the alveolar unit is a critical point. Lung inflammation, protease/antiprotease imbalance, oxidative stress and apoptosis could work together in the irreversible changes seen in emphysema [23]. Over-induc-





**Figure 5**  
**AAT-deficiency emphysema (case I):** Electron micrograph showing (a) early apoptosis with perinuclear chromatin condensation (arrow) and (b) late apoptosis with nuclear dense chromatin of pneumocytes (arrow). (c) An endothelial cell with condensed chromatin is well visible (arrow). (d) Note reduplication of the vessel basal membrane (arrow). In (e) and (f) apoptotic bodies in various degrees of degradation close to a macrophage and an intraluminal apoptotic body are well visible (arrows).





**Figure 6**  
**TGF- $\beta$ 1 expression in smoking-related vs AAT-deficiency emphysema:** the graphic shows the different cytokine expression in both types of emphysema. A significantly higher TGF- $\beta$ 1 expression was found in smoking-related emphysema versus AAT-deficiency emphysema (mean value  $8.8 \pm 1.7$  vs  $5.2 \pm 3.9$ ,  $p \leq 0.05$ ).

tion of apoptosis and inefficient cellular replenishment, modifying alveolar homeostasis, would both be expected to disrupt the alveolar wall thus inducing the development of emphysema.


Recently the causal role of apoptosis has been increasingly recognized in the destruction of alveolar walls and air-space enlargement [6-9]. Among constitutive cell populations of the alveolar wall, epithelial cells are more frequently susceptible to programmed cell death [6,9]. In our study the AI of epithelial cells was significantly higher in end-stage emphysema cases compared to the control group ( $p \leq 0.01$ ) and this was particularly more evident for those with AAT-deficiency.

To avoid a bias of under or over-estimated alveolar cell apoptosis and proliferation due to regional disease activity we analyzed large specimens taken from different lung regions (upper and lower lobes). The lower AI detected in our control lungs underlines an important concept: in non-emphysematous lungs apoptosis is an irrelevant process adequately balanced by proliferation. The increased number of apoptotic cells in patients with

emphysema (not adequately replaced by new epithelial cells) suggests a new mechanism, namely "epithelial apoptosis/proliferation imbalance" in the pathogenesis of disease. In our study, different from a recent clinical study by Yokohori et al [9], a PI similar to that of the control group was detected in the alveolar epithelial cells of emphysema patients. The discrepancies between the two studies can be attributed to several factors: 1) a different monoclonal antibody used for detection of cell proliferation (MIB1 vs PCNA); 2) different case series including patients affected by emphysema in end-stage status and overall of different types (smoking-associated and AAT-deficiency emphysema), and 3) more analysis of extensive areas (upper and lower lobes) of emphysematous lung parenchyma. Regarding the monoclonal antibody used for proliferation detection, Ki-67 is now well recognized as the most reliable immunohistochemical marker for the analysis of cell proliferation in formalin-fixed, paraffin-embedded tissue [24]. Immunoassaying for proliferating nuclear cell antigen (PCNA) can also be used in paraffin-embedded tissue, but it may overestimate the proliferation rate given the long half-life of this antigen [25]. Moreover, the simultaneous positive staining of TUNEL and PCNA in the same cells has been reported [26]. In fact, it has also been demonstrated that PCNA expression can increase without a corresponding increase in S-phase DNA synthesis [27].

DNA nicks may be seen in cells with DNA synthesis/repair thus sometimes producing false TUNEL positive cells. False positive TUNEL staining can also be generated through non-apoptotic mechanisms: RNA synthesis and splicing, necrosis as well as artifacts due to preservation methods. Consequently, some authors have stressed the importance of associating other techniques, such as *Taq* polymerase-based DNA *in situ* ligation, DNA gel electrophoresis or electron microscopy, in order to avoid false positive labeling and to assess the reliability of apoptosis [28].

Our TUNEL findings have been corroborated by employing an additional quantitative apoptosis assay. Moreover, the presence of different stages of apoptosis was confirmed and the cells involved in programmed cell death were well characterized by using electron microscopy investigation, which is considered the gold-standard technique for apoptotic cell detection. In our work double-immune labeling showed that all TUNEL positive cells were consistently negative for MIB1 thus suggesting the true epithelial DNA fragmentation. Although the high AI detected in our patients could be mainly explained by the high rate of apoptotic cell death, an impaired clearance mechanism of apoptotic cells/bodies should also be considered. A frequent finding of apoptotic bodies in alveolar walls and within lumen may support the latter theory as

**Figure 7**

**Correlation between TGF- $\beta$ RII and AI:** the graphic shows the correlation between TGF- $\beta$ RII expression and AI in controls and emphysema patients. The degree of TGF- $\beta$ RII is linearly related to the extension of apoptosis in the control group ( $p \leq 0.005$ ,  $r^2 = 0.8$ ).

an important contributing factor for a high percentage of AI.

The principal trigger of epithelial injury leading to apoptotic cell death is up to now still unclear. The cytotoxic effects of cigarette smoke, one of the most clearly proven etiologic factors in the development of emphysema and in general of COPD, have been suggested to suppress epithelial proliferation and to induce cell death. In particular oxidants and aldehydes, major constituents in the volatile phase of cigarette smoke, have been reported to induce apoptosis of lung cells [29].

Different DNA and RNA viruses have been identified as viral pathogens associated with the disease. Double-

strand DNA viruses such as adenovirus have the ability to persist in airway epithelial cells long after the acute infection has cleared. The expression of adenoviral trans-activating proteins has been demonstrated in the airway epithelium of both human and animal lungs and is associated with an amplification of cigarette smoke-induced inflammatory response [30].

Different adenovirus early proteins, in particular E4orf4, have been reported in the shutoff of host protein synthesis and in the promotion of a p53-independent cell death program [31]. It is likely that many and various noxious agents all come together to play an important role in the progression of cell death in end-stage disease, justifying the high AI in the alveolar wall, as detected in our study.

The specific molecular pathogenetic pathways that regulate both cell fate and proliferation are also under investigation. Previous studies demonstrated an inhibitory effect of the TGF- $\beta$ 1 pathway on the growth of lung epithelial cells [14,15].

As the TGF- $\beta$ 1 pathway is well-known for its anti-inflammatory activity, a higher epithelial expression of TGF- $\beta$ 1 in patients with smoking-related emphysema compared with AAT-deficiency may partially justify the different patterns of inflammation in the two types of emphysema, as found in our study. A significantly higher increase of inflammation, particularly due to T lymphocytes, was found in AAT-deficiency emphysema (panlobular type) than in smoking-related disease (centrilobular type), with the latter displaying an increased expression of the TGF- $\beta$  pathway (as demonstrated by the negative correlation with T lymphocyte infiltrate). Similar findings have been previously reported in both *in vitro* and *in vivo* studies [32,33]. An increased pro-apoptotic milieu of inflammatory related cytokines may contribute to the higher cell death rate detected in AAT-deficiency emphysema. Moreover, additional cigarette smoke-mediated damage should also be considered in AAT-deficiency emphysema patients, in that in our study they were all heavy smokers.

In our work a direct correlation between TGF- $\beta$ R2 and AI was found in the control group thus showing that this cytokine could play a role in alveolar homeostasis in physiologic conditions. Instead no correlation was found between the AI and TGF- $\beta$ 1 pathway in either type of emphysema, suggesting that the TGF- $\beta$ 1 regulated mechanism is lost in the disease. Other cytokines besides TGF- $\beta$ 1 could be involved in uncontrolled programmed cell death inducing the progressive disappearance of the alveolar unit.

Decreased expression of VEGF and VEGF R2 has been demonstrated to be significantly correlated with apoptosis of both epithelial and endothelial cells in cigarette smoking-induced emphysema [7]. It has been shown that VEGF receptor signaling is extremely important for the maintenance of alveolar structures. Hence an impairment of its trophic endothelial activity may be one of several factors facilitating alveolar septal cell apoptosis [4,7]. Significantly reduced levels of VEGF have also been detected in induced sputum of emphysema patients compared to that of normal individuals and patients with asthma [34].

More recently in an experimental model some authors have shown that over-expression of placenta growth factor (PIGF) causes a phenotype and pulmonary dysfunction similar to human lung emphysema by inducing apoptotic events in the alveolar septa [35]. Although epithelial cells have been demonstrated to be more susceptible to apop-

tosis [7], endothelial cells are also an important target for programmed cell death. Our ultrastructural analysis showed evidence of endothelial cell apoptosis mainly in those cases with more increased alveolar programmed cell death. The presence of a multi-layered vessel basement membrane, as found in many of our emphysematous lungs, may also reflect additional data supporting the increased apoptotic rate of endothelial cells.

In summary, our work has demonstrated for the first time that apoptotic phenomenon is extensive also in end-stage emphysema patients. This unique case series, and overall the large variety of lung tissue samples examined, (not only subpleural emphysematous regions as those from lung volume reduction surgery in which apoptosis could already be switched off) may account for the differences in our AI findings compared to other studies [9]. The higher rate of apoptotic cell death in patients with AAT-deficiency emphysema, partially influenced by the higher degree of inflammation, may allow us to consider this peculiar emphysema subtype as an additional modifier of apoptosis.

Whether the "apoptosis/proliferation imbalance" occurs before, after or at the same time as the "elastase/antielastase imbalance" is still unknown and should be the subject of future studies.

#### **Limitations of the study**

Our study had a few limitations. Firstly, the patients with AAT-deficiency can not be considered pure AAT-deficiency emphysema cases because these patients were also smokers. Panlobular emphysema occurs at a younger age in alpha-1-antitrypsin patients, especially if the patients smoke cigarettes, as in our case series ( $49.8 \pm 5.7$  yrs AAT-deficiency vs  $58.2 \pm 6.3$  yrs smokers,  $p \leq 0.01$ ). Patients with AAT-deficiency who are smokers develop lung impairment function earlier and in a more severe form than their non-smoking counterparts. Thus, it is extremely rare to have patients who are non-smokers with AAT-deficiency as candidates for lung transplantation. Secondly, the clinical characterization of the donor was poor and according to the guidelines for the selection of donor lungs, smokers were not excluded [36]. Smokers could have been included in the control group, and it is well known that smoking itself may induce apoptosis.

However, if this was the case, the AI difference between emphysema and control patients would have been even higher because of the lower AI in healthy patients. A third potential bias is that all the donors were mechanically ventilated before lung transplantation and it is known that mechanical ventilation may induce lung apoptosis [37]. Again, the difference observed in our study would be even higher than non-ventilated controls, thus confirming

the findings that enhanced apoptosis may act as a leading mechanism in the pathogenesis of emphysema.

## Conclusions

Our study analyzed apoptosis and proliferation in end-stage emphysema. In particular the work described for the first time a high AI in patients with AAT-deficiency emphysema. Ultrastructural investigation, TUNEL analysis and oligonucleosomal-length DNA laddering, performed in different lung regions were all used for detection of apoptotic phenomenon. The increase of apoptotic cells in patients with emphysema not adequately replaced by new epithelial cells suggests a new mechanism, namely "epithelial apoptosis/proliferation imbalance" in the pathogenesis of disease. More inflammation, particularly due to T lymphocytes, was observed in AAT-deficiency emphysematous lungs. An increased pro-apoptotic milieu of inflammatory related cytokines may contribute to the higher cell death rate detected in AAT-deficiency emphysema. While a direct correlation between TGF- $\beta$ RII and AI was found in the control group, no relation was found between the AI and TGF- $\beta$ 1 pathway in end-stage emphysema, suggesting that the influence of the TGF- $\beta$  pathway on epithelial turnover is lost in the disease. Knowledge of the mechanism responsible for activation and progression of the apoptotic cascade could offer new information in the near future, on more appropriate stratification and treatment of the disease.

## Authors' contributions

FC: conceived of the study and participated in its design and coordination

CG: substantial contribution in study design and data interpretation

BB: acquisition of clinical data and critical revision for important intellectual content

FR: thoracic surgeon providing lung specimen and critical revision for important technical aspects

ML: thoracic surgeon providing lung specimen and critical revision for important technical aspects

RZ: critical revision for important intellectual content

GP: acquisition of clinical data

SB: acquisition of clinical data and performed the statistical analysis

MS: participated in the design of the study and gave critical revision for important intellectual content

MV: substantial contribution in study design and data interpretation

All the authors read and approved the final manuscript.

## Acknowledgements

We would like to thank Alessandra Dubrovich and Giovanna Mattiazio for their excellent technical assistance and Dr. Judith Wilson for revision of the English manuscript. Sources of support: Grant Project "Chronic obstructive pulmonary disease (COPD) and lung transplantation: morphologic and molecular study of pathogenetic substrates of disease progression" and "Structure-function relationships in chronic obstructive pulmonary disease", Ministry of Education, University and Research, Rome, Italy

## References

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: **GOLD Scientific Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.** *Am J Respir Crit Care Med* 2001, **163**:1256-1276.
2. Snider GL: **Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology.** *Am Rev Respir Dis* 1989, **140**:S3-S8.
3. Hautamaki RD, Kobayashi , Senior RM, Shapiro SD: **Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice.** *Science* 1997, **277**:2002-2004.
4. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth P, Waltenberger J, Voelkel NF: **Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.** *J Clin Invest* 2000, **106**:1311-1319.
5. Aoshiba K, Yokohori N, Nagai A: **Alveolar wall apoptosis causes lung destruction and emphysematous changes.** *Am J Respir Cell Mol Biol* 2003, **28**:555-562.
6. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M: **Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD.** *Chest* 2000, **117**:684-694.
7. Kasahara Y, Tuder RM, Cool CD, Lynch CD, Flores SC, Voelkel NF: **Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema.** *Am J Respir Crit Care Med* 2001, **163**:737-744.
8. Majo J, Ghezzi H, Cosio MG: **Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema.** *Eur Respir J* 2001, **17**:946-953.
9. Yokohori N, Aoshiba K, Nagai A: **Respiratory Failure Research Group in Japan: Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema.** *Chest* 2004, **125**:626-632.
10. Massague J: **The transforming growth factor-beta family.** *Annu Rev Cell Biol* 1990, **6**:597-641.
11. Haneda K, Sano K, Tamura G, Shirota H, Ohkawara Y, Sato T, Habu S, Shirato S: **Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation: a novel high-dose tolerance in the trachea.** *Am J Respir Cell Mol Biol* 1999, **21**:268-274.
12. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Tura M, Zuin R, Beghè B, Maestrelli P, Fabbri LM, Saetta M: **Airway inflammation in childhood asthma.** *Am J Respir Crit Care Med* 2003, **168**:798-803.
13. Lutz M, Knaus P: **Integration of the TGF- $\beta$  pathway into the cellular signalling network.** *Cell Signal* 2002, **14**:977-988.
14. Hodge S, Hodge G, Flower R, Reynolds PN, Scicchitano R, Holmes M: **Up-regulation of production of TGF-beta and IL-4 and down-regulation of IL-6 by apoptotic human bronchial epithelial cells.** *Immunol Cell Biol* 2002, **80**:537-543.
15. Fjellbirkeland L, Cambier S, Broaddus VC, Hill A, Brunetta P, Dolganov G, Jablons D, Nishimura SL: **Integrin alpha beta8-mediated activation of transforming growth factorbeta inhibits human airway epithelial proliferation in intact bronchial tissue.** *Am J Pathol* 2003, **163**:533-542.

16. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Rizzo A, la Rocca AM, Bellia V, Monsignore G, Bousquet J: **Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis.** *Am J Respir Crit Care Med* 1997, **156**:591-599.
17. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A: **Increased expression of transforming growth factor-beta I in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD).** *Am J Respir Crit Care Med* 2001, **163**:1476-1483.
18. Sheppard MN: **Practical pulmonary pathology.** Edward Arnold Ed. London, UK 1995.
19. Gavrieli Y, Sherman Y, Ben-Sasson SA: **Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation.** *J Cell Biol* 1992, **119**:493-501.
20. Thompson CB: **Apoptosis in the pathogenesis and treatment of disease.** *Science* 1995, **267**:1456-1462.
21. Valente M, Calabrese F, Tiene G, Angelini A, Basso C, Nava A, Rossi L: **In Vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy.** *Am J Pathol* 1998, **152**:479-484.
22. Calabrese F, Pontisso P, Pettenazzo E, Benvegnù L, Alessandro V, Chemello L, Alberti A, Valente M: **Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels.** *Hepatology* 2000, **31**:1153-1159.
23. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM: **Apoptosis and emphysema. The missing link.** *Am J Respir Cell Mol Biol* 2003, **28**:551-554.
24. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: **Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.** *J Pathol* 1992, **168**:357-363.
25. Linden MD, Torres FX, Kubus J, Zarbo RJ: **Clinical application of morphologic and immunocytochemical assessments of cell proliferation.** *Am J Clin Pathol* 1992, **97**:S4-S13.
26. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, Noda T, Fujiwara T, Fukuda K, Minatoguchi S, Fujiwara H: **Significance of myocytes with positive DNA in situ nick end-labelling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair.** *Circulation* 1999, **99**:2757-2764.
27. Hall PA, McKee PH, Menage HD, Dover R, Lane DP: **High levels of p53 protein in UVirradiated normal human skin.** *Oncogene* 1993, **8**:203-207.
28. Kockx MM, Muhring J, Knaapen MW, de Meyer R: **RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis.** *Am J Pathol* 1998, **152**:885-888.
29. Pryor WA, Stone K: **Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxyxynitrate and peroxyxynitrite.** *ANN N Y Acad Sci* 1993, **686**:12-27.
30. Ogawa E, Elliott WM, Hughes F, Eichholtz TJ, Hogg JC, Hayashi S: **Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD.** *Am J Physiol Lung Cell Mol Physiol* 2004, **286**:L189-197.
31. Shtrichman R, Sharf R, Barr H, Dobner T, Kleinberger T: **Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A.** *Proc Natl Acad Sci USA* 1999, **96**:10080-10085.
32. Arora PK, Miller HC, Aronson LD: **Alpha-1 antitrypsin is an effector of immunological stasis.** *Nature* 1978, **274**:589-590.
33. Takubo Y, Guerassimov A, Ghezzi H, Triantafillopoulos A, Bates JH, Hoidal JR, Cosio MG: **Alpha-1-antitrypsin determines the pattern of emphysema and function in tobacco smoke-exposed mice: parallels with human disease.** *Am J Respir Crit Care Med* 2002, **166**:1596-1603.
34. Kanazawa H, Asai K, Hirata K, Yoshikawa J: **Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease.** *Am J Med* 2003, **114**:354-358.
35. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, Lee CN, Chen CA, Cheng WF, Wie SC, Yu CJ, Hsieh FJ, Hsu SM: **Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema.** *Am J Respir Crit Care Med* 2004, **169**:505-511.
36. Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, Kotloff R, Morton J, Studer SM, Van Raemdonck D, Waddell T, Snell G: **Pulmonary Council, International Society for Heart and Lung Transplantation: A review of lung transplant donor acceptability criteria.** *J Heart Lung Transplant* 2003, **22**:1183-1200.
37. May M, Ströbel P, Preissshofen T, Seidenspinner S, Marx A, Speer CP: **Apoptosis and proliferation in lungs ventilated and oxygen-treated preterm infants.** *Eur Respir J* 2004, **23**:113-121.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

